RxDoctor Payments Data

Ray Page, DO

Hematology & Oncology · Weatherford, TXNPI 1669422143

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.8%. Reporting peaked in 2023 at $17,237 and has fallen 81.0% since, to $3,275 in 2025.

$45,070in general payments, 2019–2025

Across 621 payments — averaging $72.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$5K
  • Verastem, Inc.$5K
  • Astellas Pharma US Inc$4K
  • AbbVie$4K
  • Puma Biotechnology, Inc.$3K
  • Johnson & Johnson$3K
  • plus $20K from 54 others
$2,390,595in research payments, 2019–2025

Across 343 payments — averaging $6969.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$691K
  • Incyte Corporation$346K
  • Eli Lilly$259K
  • Genentech, Inc.$220K
  • Exelixis Inc.$174K
  • GSK$118K
  • plus $583K from 18 others

What the payments were for

  • Consulting fees$20,42645%
  • Speaking & faculty fees$7,20016%
  • Travel & lodging$5911%
  • Food & beverage$16,26636%
  • Education$5871%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.34$5,341
Verastem, Inc.5$5,185
Astellas Pharma US Inc12$4,115
AbbVie13$3,807
Puma Biotechnology, Inc.24$3,205
Johnson & Johnson(2 entities)27$3,004
Jazz Pharmaceuticals Inc.3$2,435
Takeda Pharmaceuticals U.S.A., Inc.15$2,240
G1 Therapeutics, Inc.2$1,515
Regeneron3$1,208
Novartis30$881
E.r. Squibb & Sons, L.L.C.34$763
Genentech USA, Inc.14$687
Gilead(2 entities)18$686
Pfizer38$677
AstraZeneca34$674
Merck29$618
Incyte Corporation18$441
Lilly USA, LLC23$428
Amgen12$382
Bayer14$375
Ipsen Biopharmaceuticals, Inc7$304
Sanofi13$294
Pharmacosmos Therapeutics Inc.3$291
Exelixis Inc.7$289
Bristol Myers Squibb14$283
Immunocore Limited4$271
GSK10$266
Regeneron Healthcare Solutions, Inc.7$247
Seagen Inc.9$197
Sirtex Medical Inc4$191
Eisai Inc.9$188
Stemline Therapeutics Inc.4$179
Genmab U.S., Inc.5$176
Blueprint Medicines Corporation3$166
Novocure Inc.2$160
Spectrum Pharmaceuticals Inc.4$152
Tempus AI, Inc4$149
EMD Serono, Inc.7$148
Caris MPI, Inc.2$145
Sobi, Inc7$137
Pharmaessentia USA Corporation4$131
Teva Pharmaceuticals USA, Inc.4$126
Intuitive Surgical1$125
Boehringer Ingelheim5$116
Taiho Oncology, Inc.6$106
Array Biopharma Inc5$97
ASD Specialty Healthcare, LLC1$97
Helsinn Therapeutics (U.S.), Inc.1$94
Rigel Pharmaceuticals, Inc.5$85
Karyopharm Therapeutics Inc.4$79
Servier Pharmaceuticals LLC3$70
Acrotech Biopharma Inc.4$63
Tesaro, Inc.4$60
ADC Therapeutics America, Inc.3$54
Beone Medicines USA, Inc.3$51
TG Therapeutics, Inc.1$50
Beigene USA, Inc.3$48
Apellis Pharmaceuticals, Inc.2$46
Mirati Therapeutics, Inc.2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,070 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$4,020,807
Medicare patients
433
Services billed
199,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide39$620,878
ImbruvicaIbrutinib40$481,508
ErleadaApalutamide29$432,347
LonsurfTrifluridine/Tipiracil Hcl26$425,940
JakafiRuxolitinib Phosphate22$368,771
Lenalidomide24$359,049
CabometyxCabozantinib S-Malate14$356,365
VerzenioAbemaciclib17$254,478
TagrissoOsimertinib Mesylate13$207,882
Imatinib Mesylate34$104,292
BrukinsaZanubrutinib12$84,972
Abiraterone Acetate48$68,755
EliquisApixaban29$28,730
Exemestane23$2,327
Anastrozole141$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$283$620,87839 claims
Johnson & JohnsonErleada$3,004$432,34729 claims
Taiho Oncology, Inc.Lonsurf$106$425,94026 claims
Incyte CorporationJakafi$441$368,77122 claims
Exelixis Inc.Cabometyx$289$356,36514 claims
Lilly USA, LLCVerzenio$428$254,47817 claims
AstraZenecaTagrisso$674$207,88213 claims
Beigene USA, Inc.Brukinsa$48$84,97212 claims
PfizerEliquis$677$28,73029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 838 hematology & oncology providers in Texas.

Other hematology & oncology in Weatherford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →